Phenotypes associated with this allele
|
Find Mice |
Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Gt(ROSA)26Sortm3(CAG-MIR17-92,-EGFP)Rsky mutation
(1 available);
any
Gt(ROSA)26Sor mutation
(811 available)
Tg(CD2-icre)4Kio mutation
(4 available)
|
|
|
immune system
|
• mice exhibit more CD19+B220loCD5+CD43+CD23- B-1a cells in the spleen and peritoneal cavity compared to in wild-type mice
|
hematopoietic system
|
• mice exhibit more CD19+B220loCD5+CD43+CD23- B-1a cells in the spleen and peritoneal cavity compared to in wild-type mice
|
|
Find Mice |
Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Gt(ROSA)26Sortm3(CAG-MIR17-92,-EGFP)Rsky mutation
(1 available);
any
Gt(ROSA)26Sor mutation
(811 available)
Tg(CD2-icre)4Kio mutation
(4 available)
|
|
|
growth/size/body
|
• spleens and lymph nodes are enlarged up to 30-fold in terms of weight and cell number compared to in wild-type mice
|
|
• spleens and lymph nodes are enlarged up to 30-fold in terms of weight and cell number compared to in wild-type mice
|
cellular
|
• B-2 cell proliferation is enhanced following activation with anti-IgM or lipopolysaccharides unlike in wild-type cells
|
mortality/aging
|
• all mice die by 55 weeks of age
|
immune system
N |
• despite increased immunoglobulin, cytokine levels in the blood are normal
|
|
• spleens and lymph nodes are enlarged up to 30-fold in terms of weight and cell number compared to in wild-type mice
|
|
• spleens and lymph nodes are enlarged up to 30-fold in terms of weight and cell number compared to in wild-type mice
|
|
• prior to 14 weeks of age, mice exhibit a 2-fold higher percentage of thymocytes at the double negative stage compared to in wild-type mice
• however, the total number of thymocytes is unchanged
|
|
• in the spleen and peripheral lymph nodes
|
|
• mice exhibit more CD19+B220loCD5+CD43+CD23- B-1a cells in the spleen and peritoneal cavity compared to in wild-type mice
|
|
• spleen and lymph node B cells exhibit increased cell size compared to in wild-type mice
|
|
• CD4+ T cells exhibit increased proliferation and survival following stimulation with CD3 alone unlike wild-type cells
|
|
• the spleen marginal zone is disrupted unlike in wild-type mice
|
|
• spleens and lymph nodes are enlarged up to 30-fold in terms of weight and cell number compared to in wild-type mice
|
|
• spleens and lymph nodes are enlarged up to 30-fold in terms of weight and cell number compared to in wild-type mice
|
|
• mice exhibit massive infiltration of lymphocytes into the salivary glands and lungs with some infiltration of the kidneys unlike in wild-type mice
|
|
• B cells are more resistance than in wild-type mice to Fas-mediated cell death following activation
• activated B cells exhibit enhanced proliferation and survival compared to wild-type cells
|
|
• B-2 cell proliferation is enhanced following activation with anti-IgM or lipopolysaccharides unlike in wild-type cells
|
|
• 4- to 6-fold at 8 to 12 weeks of age
|
|
• 4- to 6-fold at 8 to 12 weeks of age
|
|
• 4- to 6-fold at 8 to 12 weeks of age
|
|
• 4- to 6-fold at 8 to 12 weeks of age
|
|
• more CD4+ T cells produce IFN-gamma and IL-10 but not IL-4 or TNF than wild-type cells
• CD4+T cells from older mice produce more IFN-gamma and IL-10 than CD4+ T cells from younger mice
|
|
• activated T cells exhibit enhanced proliferation and survival compared to wild-type cells
|
renal/urinary system
|
• a subset of mice show marked accumulation of IgG and the C3d component of complement in the mesangium and segmentally in the periphery of glomeruli
|
|
• mice exhibit mesangial expansion unlike in wild-type mice
|
|
• mice exhibit enlarged renal glomeruli with hypercellularity and mesangial expansion unlike in wild-type mice
|
homeostasis/metabolism
hematopoietic system
|
• spleens and lymph nodes are enlarged up to 30-fold in terms of weight and cell number compared to in wild-type mice
|
|
• spleens and lymph nodes are enlarged up to 30-fold in terms of weight and cell number compared to in wild-type mice
|
|
• prior to 14 weeks of age, mice exhibit a 2-fold higher percentage of thymocytes at the double negative stage compared to in wild-type mice
• however, the total number of thymocytes is unchanged
|
|
• in the spleen and peripheral lymph nodes
|
|
• mice exhibit more CD19+B220loCD5+CD43+CD23- B-1a cells in the spleen and peritoneal cavity compared to in wild-type mice
|
|
• spleen and lymph node B cells exhibit increased cell size compared to in wild-type mice
|
|
• CD4+ T cells exhibit increased proliferation and survival following stimulation with CD3 alone unlike wild-type cells
|
|
• the spleen marginal zone is disrupted unlike in wild-type mice
|
|
• B cells are more resistance than in wild-type mice to Fas-mediated cell death following activation
• activated B cells exhibit enhanced proliferation and survival compared to wild-type cells
|
|
• B-2 cell proliferation is enhanced following activation with anti-IgM or lipopolysaccharides unlike in wild-type cells
|
|
• 4- to 6-fold at 8 to 12 weeks of age
|
|
• 4- to 6-fold at 8 to 12 weeks of age
|
|
• 4- to 6-fold at 8 to 12 weeks of age
|
|
• 4- to 6-fold at 8 to 12 weeks of age
|
|
• more CD4+ T cells produce IFN-gamma and IL-10 but not IL-4 or TNF than wild-type cells
• CD4+T cells from older mice produce more IFN-gamma and IL-10 than CD4+ T cells from younger mice
|
|
• activated T cells exhibit enhanced proliferation and survival compared to wild-type cells
|